scholarly journals Relationship between muscle strength and rehospitalization in ventricular assist device patients

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Kiyonori Kobayashi ◽  
Masato Mutsuga ◽  
Akihiko Usui
Keyword(s):  
Muscle Strength ◽  
Grip Strength ◽  
Ventricular Assist Device ◽  
Laboratory Data ◽  
Walk Distance ◽  
Assist Device ◽  
Ventricular Assist ◽  
Rehospitalization Rate ◽  
Strength Group ◽  
The Relationship

AbstractWe examined the relationship between leg extensor muscle strength (LEMS) at discharge and rehospitalization within 1 year in patients with a newly implanted ventricular assist device (VAD). This study included 28 patients who had received a VAD at our institution between October 2013 and February 2019, all of whom had been discharged for 1 year. The patients were divided into two groups according to their LEMS at discharge (higher strength [group H] and lower strength [group L]), based on the median value of the 55.2 kg-force (kgf)/body weight (BW) equation. Exercise performance parameters (e.g., grip strength, 6-min walk distance, and peak VO2) and laboratory data concerning nutritional status were also collected. Nine patients (64.3%) in group L were rehospitalized within 1 year after discharge. The rehospitalization rate was significantly higher in group L than group H (p = 0.020). Compared with discharge, patients exhibited higher grip strength (56.3 vs. 48.6 kg/BW, respectively; p = 0.011), 6-min walk distances (588 vs. 470 m, respectively; p = 0.002), and peak VO2 (15.4 vs. 11.9 mL/min/kg, respectively; p < 0.001) at 1 year after discharge. However, the LEMS (57.4 vs. 58.0 kgf/BW, respectively; p = 0.798) did not increase after discharge in VAD patients who avoided rehospitalization. LEMS at discharge was associated with rehospitalization after VAD surgery; a high LEMS improves the likelihood of avoiding rehospitalization.

The Relationship Between R-Wave Magnitude and Ventricular Volume During Continuous Left Ventricular Assist Device Assistance: Experimental Study

2014 ◽  
Vol 39 (5) ◽  
pp. 446-450 ◽  
Author(s):  
Libera Fresiello ◽  
Maria Giovanna Trivella ◽  
Arianna Di Molfetta ◽  
Gianfranco Ferrari ◽  
Fabio Bernini ◽  
...  
Keyword(s):  
Experimental Study ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Ventricular Volume ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
The Relationship

scholarly journals Argatroban versus heparin for the treatment of pump thrombosis in patients with ventricular assist device

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Dantas Ferreira Fernandes ◽  
G.C Fernandes ◽  
S Chaparro
Keyword(s):  
Ventricular Assist Device ◽  
Laboratory Data ◽  
Small Sample ◽  
Rank Test ◽  
Assist Device ◽  
Ventricular Assist ◽  
Pump Function ◽  
Anticoagulation Treatment ◽  
Pump Thrombosis

Abstract Background/Introduction Pump thrombosis (PT) is a major complication from ventricular assist device (VAD) and the best therapy remains unknown. The diagnosis of PT is challenging and, based on the ISHLT (International Society of Heart and Lung Transplantation) guidelines, consists of signs of hemolysis and impaired pump function. Purpose We aimed to compare the outcomes of PT treated with continuous infusion of argatroban (ARG) versus heparin. Methods This is a retrospective cohort study including patients &gt;15 years-old with VAD implanted between 2009 and 2017 and who developed PT during follow up. PT events were managed with ARG or heparin based on physician preference at our institution, and patients were grouped based on the anticoagulation treatment received. Variables of interest were survival at 1, 3 and 5 years, stroke, right heart failure (RHF), infection, laboratory data and VAD parameters before and after anticoagulation treatment, baseline characteristics and comorbidities. We used Chi-square test to analyze categorical data and the Wilcoxon signed rank test for continuous data in related samples to compare laboratory and VAD parameters pre and post anticoagulation in both groups. Kaplan Meier survival analysis was performed using the log rank statistics. Non-parametric results were reported as median and interquartile range (IQR). A 95% confidence interval (CI) was adopted. Results There were 193 VADs implanted in 170 patients. Of those, 30 patients had 47 episodes of PT, 34 treated with ARG and 13 with heparin. Of patients with PT, 73% had a HeartMate II and 27% had a HeartWare device, the median age at implantation was 48 years old (IQR 40.2, 60.2) and 90% were males; African Americans were 50%, followed by Hispanics (30%) and Caucasians (20%). The median follow-up was 2.5 years (IQR 1, 3.4). In the ARG group, there was a statistically significant reduction at the time of discharge in LDH (p&lt;0.001), AST (p&lt;0.001), total bilirubin (p=0.001), platelet count (p=0.046), VAD flow (p=0.011) and VAD power (p=0.004) compared with admission parameters, while no statistically significant change was present in the heparin group. ARG led to a numerically higher, but not statistically significant, survival when compared with heparin (53% vs 38%, p=0.237). One-year, 3-year and 5-year survival were not significantly different between anticoagulation strategies (p=0.23, p=0.9 and p=0.89, respectively). There was no difference in the number of VAD re-implants, RHF, stroke or infection between groups. Conclusions ARG therapy led to a statistically significant improvement in hemolysis parameters and pump function when compared to heparin therapy for PT in VAD recipients, but no survival benefit was demonstrated, which could be due to the small sample size. Other limitations were the retrospective and non-randomized data. ARG therapy must be tested in larger trials to confirm its benefits for PT. Funding Acknowledgement Type of funding source: None

scholarly journals The Relationship Between Psychological Symptoms and Ventricular Assist Device Implantation

2017 ◽  
Vol 54 (6) ◽  
pp. 870-876.e1 ◽  
Author(s):  
Himali Weerahandi ◽  
Nathan Goldstein ◽  
Laura P. Gelfman ◽  
Ulrich Jorde ◽  
James N. Kirkpatrick ◽  
...  
Keyword(s):  
Ventricular Assist Device ◽  
Psychological Symptoms ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Implantation ◽  
The Relationship

Improved 6 Minute Walk Distance and Brain-Type Natriuretic Peptide After Continuous-Flow Ventricular Assist Device Placement in Children

ASAIO Journal ◽  
2019 ◽  
Vol 65 (7) ◽  
pp. 725-730
Author(s):  
Jason F. Goldberg ◽  
Robin S. Schlosser ◽  
James G. Walrath ◽  
Shaine A. Morris ◽  
Barbara A. Elias ◽  
...  
Keyword(s):  
Natriuretic Peptide ◽  
Ventricular Assist Device ◽  
Continuous Flow ◽  
Walk Distance ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Placement ◽  
Minute Walk Distance ◽  
Minute Walk
Sign in / Sign up

Export Citation Format

Share Document